5/10/2013

The FDA has accepted Merck & Co.'s biologics-license application for a dissolvable immunotherapy tablet for ragweed pollen allergy. Merck expects the FDA to release its decision in the first half of next year. The sublingual tablet was developed in collaboration with ALK-Abello.

Full Story:
Fox Business

Related Summaries